Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
Panelists discuss how clinical trial data from CARTITUDE-1, CARTITUDE-4, and KarMMa-3 demonstrate the efficacy of CAR T therapies cilta-cel and ide-cel in multiple myeloma, comparing their real-world outcomes and considering patient-specific factors for treatment selection.
Video content above is prompted by the following:
- Let’s start by discussing the treatment landscape and data with CAR T therapy in multiple myeloma. Please highlight pivotal data:
- CARTITUDE-1/CARTITUDE-4
- KarMMa-3
- In which patients do you consider cilta-cel vs ide-cel? Has real-world practice reflected efficacy and safety data from these trials?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
